Establishment Labs Holdings Inc.
HealthcareNASDAQ:ESTA · NASDAQ Capital Market
-$2.97 today
Vol 0.47M · Avg 0.50M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$229.6M of revenue converted into -$43.7M of net income for the selected period. Gross margin is 70.0% and net margin is -19.9%, showing how much revenue survives after costs and taxes. EPS is $-1.48, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $211.1M +27.1% | $166.0M +0.5% | $165.2M +2.1% | $161.7M +27.6% | $126.7M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $64.8M +14.6% | $56.5M -2.9% | $58.2M +5.6% | $55.1M +33.5% | $41.3M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $146.3M +33.6% | $109.5M +2.4% | $107.0M +0.4% | $106.6M +24.8% | $85.4M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 69.3% +3.3pp | 66.0% +1.2pp | 64.8% -1.1pp | 65.9% -1.5pp | 67.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $20.2M +2.7% | $19.7M -25.4% | $26.4M +30.4% | $20.3M +10.7% | $18.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $165.1M +18.1% | $139.8M -4.0% | $145.6M +15.6% | $126.0M +36.6% | $92.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $185.3M +16.2% | $159.5M -7.3% | $172.0M +17.6% | $146.3M +32.3% | $110.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $0 -100.0% | $7.6M +55.2% | $4.9M +17.1% | $4.2M +1.5% | $4.1M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$32.8M +41.7% | -$56.2M +3.6% | -$58.3M -2.5% | -$56.9M -114.3% | -$26.5M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -15.5% +18.3pp | -33.9% +1.4pp | -35.3% -0.1pp | -35.2% -14.2pp | -21.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$39.0M +22.0% | -$50.0M +23.1% | -$65.0M -64.0% | -$39.7M -57.7% | -$25.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -18.5% +11.6pp | -30.1% +9.3pp | -39.4% -14.8pp | -24.5% -4.7pp | -19.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $423.0K -71.4% | $1.5M +44.8% | $1.0M +1072.4% | $87.0K +278.3% | $23.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $25.3M +21.3% | $20.8M +35.3% | $15.4M +30.9% | $11.8M +29.8% | $9.1M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$19.0M +45.1% | -$34.6M -155.5% | -$13.6M +59.1% | -$33.2M -127.6% | -$14.6M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$58.0M +31.4% | -$84.6M -7.7% | -$78.6M -7.9% | -$72.8M -83.4% | -$39.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -27.5% +23.5pp | -51.0% -3.4pp | -47.6% -2.5pp | -45.0% -13.7pp | -31.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$7.0M -21643.8% | -$32.0K +60.5% | -$81.0K -103.4% | $2.4M +67.1% | $1.4M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$51.1M +39.6% | -$84.6M -7.8% | -$78.5M -4.4% | -$75.2M -82.8% | -$41.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | -24.2% +26.8pp | -51.0% -3.4pp | -47.5% -1.0pp | -46.5% -14.0pp | -32.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 +42.7% | -$3 +2.3% | -$3 +0.3% | -$3 -79.1% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 +42.7% | -$3 +2.3% | -$3 +0.3% | -$3 -79.1% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $29.6M +5.2% | $28.2M +10.0% | $25.6M +4.7% | $24.5M +2.0% | $24.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $29.6M +5.2% | $28.2M +10.0% | $25.6M +4.7% | $24.5M +2.0% | $24.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$4.88B
NovoCure Limited
NASDAQ:NVCR
$2.06B
UFP Technologies, Inc.
NASDAQ:UFPT
$1.82B
Zymeworks Inc.
NASDAQ:ZYME
$1.68B
AdaptHealth Corp.
NASDAQ:AHCO
$1.38B
Teladoc Health, Inc.
NYSE:TDOC
$1.32B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.22B
CONMED Corporation
NYSE:CNMD
$1.05B
Azenta, Inc.
NASDAQ:AZTA
$1.04B
SS Innovations International, Inc.
NASDAQ:SSII
$672.44M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ESTA generate?
Establishment Labs Holdings Inc. (ESTA) reported $211.08M of revenue in fiscal 2025.
Is ESTA profitable?
Establishment Labs Holdings Inc. (ESTA) reported -$51,064,000.00 of net income, with a net margin of -24.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.